(Q33646066)

28 July 2017

1 reference

title

The cost of treating dyslipidaemia using National Cholesterol Education Program (NCEP) guidelines (English)

1 reference

28 July 2017

1 reference

McKenney JM

1

1 reference

28 July 2017

publication date

1 January 1998

1 reference

28 July 2017

1 reference

28 July 2017

volume

14 Suppl 3

1 reference

28 July 2017

page(s)

19-28

1 reference

https://scigraph.springernature.com/pub.10.2165/00019053-199814003-00003

28 July 2017

exact match

0 references

cites work

Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group

1 reference

12 December 2020

Economics of coronary artery bypass grafting

1 reference

12 December 2020

Monotherapy with HMG-CoA reductase inhibitors and secondary prevention in coronary artery disease

1 reference

12 December 2020

Relative risk reduction versus number needed to treat as measures of lipid-lowering trial results

1 reference

12 December 2020

A British Cardiac Society survey of the potential for the secondary prevention of coronary disease: ASPIRE (Action on Secondary Prevention through Intervention to Reduce Events).

1 reference

12 December 2020

Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study

1 reference

12 December 2020

The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators

1 reference

12 December 2020

Cost implications of lipid-lowering treatments

1 reference

12 December 2020

Five‐Hundred Life‐Saving Interventions and Their Cost‐Effectiveness

1 reference

12 December 2020

Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study)

1 reference

12 December 2020

Cost-effectiveness of cholesterol lowering. Results from the Scandinavian Simvastatin Survival Study (4S)

1 reference

12 December 2020

Treatment patterns and distribution of low-density lipoprotein cholesterol levels in treatment-eligible United States adults

1 reference

12 December 2020

Inadequate treatment with HMG-CoA reductase inhibitors by health care providers

1 reference

12 December 2020

Prediction of Coronary Heart Disease Using Risk Factor Categories

1 reference

12 December 2020

Cost-effectiveness of pravastatin in secondary prevention of coronary artery disease

1 reference

12 December 2020

The cost of reaching National Cholesterol Education Program (NCEP) goals in hypercholesterolaemic patients. A comparison of atorvastatin, simvastatin, lovastatin and fluvastatin

1 reference

12 December 2020

Distribution of lipids in 8,500 men with coronary artery disease. Department of Veterans Affairs HDL Intervention Trial Study Group

1 reference

12 December 2020

Cost effectiveness of lowering cholesterol concentration with statins in patients with and without pre-existing coronary heart disease: life table method applied to health authority population

1 reference

12 December 2020

Strategies for the management of hypercholesterolaemia: a systematic review of the cost-effectiveness literature.

1 reference

12 December 2020

Cholesterol lowering and mortality: the importance of considering initial level of risk

1 reference

12 December 2020

Economic consequences of postinfarction prophylaxis with beta blockers: cost effectiveness of metoprolol

1 reference

12 December 2020

Primary prevention of coronary heart disease: guidance from Framingham: a statement for healthcare professionals from the AHA Task Force on Risk Reduction. American Heart Association

1 reference

12 December 2020

Cost-benefit aspects of post-myocardial infarction intervention

1 reference

12 December 2020

National Cholesterol Education Program. Second Report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II)

1 reference

12 December 2020

Clofibrate and niacin in coronary heart disease

1 reference

12 December 2020

Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin

1 reference

12 December 2020

Reduction in coronary events during treatment with pravastatin. PLAC I and PLAC II Investigators. Pravastatin Limitation of Atherosclerosis in the Coronary Arteries

1 reference

12 December 2020

Lipid-lowering for prevention of coronary heart disease: what policy now?

1 reference

12 December 2020

Cholesterol lowering and the use of healthcare resources. Results of the Scandinavian Simvastatin Survival Study.

1 reference

12 December 2020

The cost effectiveness of lipid lowering in Swedish primary health care. The CELL Study Group

1 reference

12 December 2020

Lipids, risk factors and ischaemic heart disease

1 reference

12 December 2020

Use of statins. Health authorities must work with clinicians to target statins

1 reference

12 December 2020

Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease

1 reference

12 December 2020

The Lipid Research Clinics Coronary Primary Prevention Trial results. II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering

1 reference

12 December 2020

Costs and effectiveness of routine therapy with long-term beta-adrenergic antagonists after acute myocardial infarction

1 reference

12 December 2020

Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)

1 reference

12 December 2020

Myocardial revascularization for chronic stable angina. Analysis of the role of percutaneous transluminal coronary angioplasty based on data available in 1989.

1 reference

12 December 2020

Cholesterol reduction yields clinical benefit: impact of statin trials

1 reference

12 December 2020

The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease

1 reference

12 December 2020

The West of Scotland coronary prevention study: economic benefit analysis of primary prevention with pravastatin.

1 reference

12 December 2020

Baseline risk factors and their association with outcome in the West of Scotland Coronary Prevention Study. The West of Scotland Coronary Prevention Study Group

1 reference

12 December 2020

Cost effectiveness of simvastatin treatment to lower cholesterol levels in patients with coronary heart disease. Scandinavian Simvastatin Survival Study Group.

1 reference

12 December 2020

Cost-effectiveness of coronary artery bypass surgery

1 reference

12 December 2020

Prevention of coronary heart disease in clinical practice. Recommendations of the Task Force of the European Society of Cardiology, European Atherosclerosis Society and European Society of Hypertension

1 reference

12 December 2020

Cholesterol and coronary heart disease. The 21st century

1 reference

12 December 2020

10.2165/00019053-199814003-00003

Identifiers

DOI

0 references

Dimensions Publication ID

1043300577

0 references

1 reference